TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02660359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study: NCT01748695
Drug: V158866
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01748695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01335711
Drug: ChronVac-C + SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
Study: NCT01335711
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
Study: NCT00761501
Drug: Naproxen (Proxen S)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00761501
Drug: Naproxen (Naprosyn E)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01070355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules taken twice daily for 2-6 weeks before liver resection.
Study: NCT03618225
Drug: placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
Study: NCT00997412
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 mg/tablet, 4 tablets twice daily
Study: NCT03604328
Drug: PA5108
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ocular implant, administered on day 1
Study: NCT02747628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
Study: NCT02747628
Drug: transdermal therapeutic system- melatonin.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
Study: NCT00399802
Drug: ZA matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of ZA matching placebo given at the start of treatment
Study: NCT00492921
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00652093
Drug: opana then darvocet then placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
Study: NCT00652093
Drug: Placebo then darvocet then opana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
Study: NCT00652093
Drug: Darvocet then opana then placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
Study: NCT00652093
Drug: Darvocet then placebo then opana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
Study: NCT03649971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC will be administered every 4 weeks.
Study: NCT03167164
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03167164
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03167164
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT02536508
Drug: BGF MDI 320/14.4/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate
Study: NCT02536508
Drug: GFF MDI 14.4/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium and Formoterol Fumarate
Study: NCT02536508
Drug: BFF MDI 320/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and Formoterol Fumarate
Study: NCT04570449
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg capsule
Study: NCT04570449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxetine placebo capsule
Study: NCT01346137
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
Study: NCT02064218
Drug: Anti-hypertensive drugs
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02924675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses daily with lactose
Study: NCT01070875
Drug: Variation of heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
Study: NCT01070875
Drug: Variation of heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
Study: NCT00477529
Drug: ABI-008
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-docetaxel
Study: NCT03562780
Drug: Fortolin Tab 500mg
Normalized name: Fortolin 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
Study: NCT03562780
Drug: Panadol Caplet 500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
Study: NCT03956303
Drug: Chirocaine %0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
Study: NCT02973958
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See active comparator description
Study: NCT02973958
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See active comparator description
Study: NCT03488810
Drug: Non-steroidal anti-androgen
Normalized name: Anti-androgens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
Study: NCT00472927
Drug: Premarin/MPA 0.45 mg/1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05417529
Drug: Standard Preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
Study: NCT02228512
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
Study: NCT00007020
Drug: Cholic Acids
Normalized name: PEPSIN W/BILE SALTS/DEHYDROCHOLIC ACIDS TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 mg/kg body weight/day taken orally.
Study: NCT02516319
Drug: ICG Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02973958
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See experimental arm description
Study: NCT02228512
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part B: 750 mg/m2 Day 5
Study: NCT01415440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosing will parallel that of Lisdexamfetamine.
Study: NCT02232529
Drug: MIN-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02232529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00213018
Drug: Carraguard (PC-515)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04083222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 757456-matching placebo solution administered as SC injection.
Study: NCT02240498
Drug: 20% I.V. Fat Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
Study: NCT00600600
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline dosage based on age and clinical status of patient.
Study: NCT01775137
Drug: TBM100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin inhalation powder (TIP) 112mg/b.i.d
Study: NCT01605305
Drug: FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
Study: NCT02446652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally) starting 1 week before the first day of the QT
Study: NCT04111341
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
Study: NCT03372954
Drug: BMAC
Normalized name: Bone Marrow Aspirate Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: retrograde administration on non-selected BMAC via coronary sinus
Study: NCT00241111
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02345161
Drug: Triple FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
Study: NCT00598962
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage dependent on clinical factors such as age, weight and patient-specific health status
Study: NCT04210973
Drug: Anyu Peibo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
Study: NCT04210973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule, twice per day, oral after breakfast and supper
Study: NCT04329923
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00887445
Drug: SLV341
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 - 1000mg once daily
Study: NCT00887445
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04546256
Drug: ADVAIR DISKUS® 500/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT02046564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01040130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of low and high dose and placebo on exercise endurance time in COPD patients
Study: NCT00990015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution/suspension to match active drug QD at a single dose.
Study: NCT00168012
Drug: Immunoglobulins Intravenous (Human)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00562510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID added to stable HAART
Study: NCT00973908
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
Study: NCT00973908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
Study: NCT00949650
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 once daily until progression
Study: NCT03247998
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
Study: NCT03247998
Drug: Conscious Sedation with Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
Study: NCT02168946
Drug: Best Available Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic(s) chosen by Investigator
Study: NCT03414918
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
Study: NCT02457897
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral supplement given every 8 hours
Study: NCT03401177
Drug: Naproxen 500 Mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
Study: NCT01852344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mgs of methylphenidate or a placebo to be administered one hour before task performance
Study: NCT02307305
Drug: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
Study: NCT02296840
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 10mg/kg/day every 6-8 hours
Study: NCT02675517
Drug: Spiolto Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium bromide + Olodaterol
Study: NCT01832311
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
Study: NCT00187161
Drug: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The additional information is contained in the Detailed Description section.
Study: NCT01963052
Drug: AGS15E
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) infusion
Study: NCT00743353
Drug: F-18 RGD-K5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
Study: NCT01046643
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
Study: NCT01030042
Drug: FOLFOX-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
Study: NCT04110834
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
Study: NCT02893722
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
Study: NCT02976467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets are given twice daily over a treatment period of 6 months
Study: NCT04441931
Drug: LY3832479
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT04441931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT00379938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control
Study: NCT01161524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo taken once daily.
Study: NCT00339079
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
Study: NCT00339079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
Study: NCT04674137
Drug: XC8 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
Study: NCT04674137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
Study: NCT02365532
Drug: Placebo to match GS-6615
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GS-6615 tablets administered orally
Study: NCT01618656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT00127218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo pill daily for 18 months
Study: NCT00493389
Drug: Adrenocorticotrophic hormone
Normalized name: Adrenocorticotrophic hormone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01063205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
Study: NCT00299884
Drug: Combination Ezetrol 10 mg and Lipidil Supra 160 mg
Normalized name: Supra Sulfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: a/a for 6 weeks
Study: NCT01052012
Drug: SABER-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Solution; SABER-Placebo/Once
Study: NCT00502710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo po daily.